Q1 2025 EPS Estimates for Incyte Co. (NASDAQ:INCY) Boosted by William Blair

Incyte Co. (NASDAQ:INCY) – Equities research analysts at William Blair boosted their Q1 2025 earnings estimates for shares of Incyte in a research report issued on Tuesday, April 23rd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $0.90 per share for the quarter, up from their previous forecast of $0.71. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the firm earned $0.44 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis.

A number of other equities research analysts have also recently issued reports on the stock. Oppenheimer decreased their price objective on shares of Incyte from $92.00 to $84.00 and set an “outperform” rating for the company in a report on Wednesday. BMO Capital Markets upped their price objective on shares of Incyte from $58.00 to $64.00 and gave the stock a “market perform” rating in a report on Wednesday, February 14th. Cantor Fitzgerald assumed coverage on shares of Incyte in a report on Tuesday. They issued a “neutral” rating for the company. Stifel Nicolaus upped their price objective on shares of Incyte from $67.00 to $68.00 and gave the stock a “hold” rating in a report on Wednesday, February 14th. Finally, Citigroup decreased their price objective on shares of Incyte from $82.00 to $81.00 and set a “buy” rating for the company in a report on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $75.50.

Incyte Trading Up 1.0 %

Shares of NASDAQ:INCY opened at $51.68 on Thursday. The stock has a market capitalization of $11.60 billion, a PE ratio of 19.50, a P/E/G ratio of 1.20 and a beta of 0.65. Incyte has a 1 year low of $50.27 and a 1 year high of $75.74. The firm has a fifty day moving average price of $56.78 and a 200 day moving average price of $57.70. The company has a current ratio of 3.55, a quick ratio of 3.36 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in INCY. Norges Bank acquired a new position in shares of Incyte during the fourth quarter valued at about $123,253,000. LSV Asset Management raised its position in shares of Incyte by 119.6% during the fourth quarter. LSV Asset Management now owns 2,691,827 shares of the biopharmaceutical company’s stock valued at $169,020,000 after buying an additional 1,465,792 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Incyte by 2,858.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,025,784 shares of the biopharmaceutical company’s stock valued at $64,409,000 after buying an additional 991,110 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of Incyte by 585.8% during the third quarter. Los Angeles Capital Management LLC now owns 1,145,362 shares of the biopharmaceutical company’s stock valued at $66,168,000 after buying an additional 978,342 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Incyte by 56.6% in the third quarter. Acadian Asset Management LLC now owns 2,684,621 shares of the biopharmaceutical company’s stock valued at $155,053,000 after acquiring an additional 970,668 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.